From BMT to CAR T
January 25, 2018
| by City of Hope
Stephen J. Forman, BMT pioneer, pictured here in the late 1970s
City of Hope’s history with CAR T cell therapy dates back to the late 1990s and builds on Stephen J. Forman
, M.D.’s pioneering work in bone marrow transplantation (BMT). The City of Hope BMT program began in 1976 and has since grown into one of the largest, most successful programs of its kind in the nation. To date, more than 14,000 bone marrow transplants have been performed at City of Hope, with survival rates exceeding expectations for 13 consecutive years.
Currently, City of Hope is investigating CAR T cell therapy as a bridge to bone marrow transplant for leukemia and lymphoma patients and is unique in its research of CAR T in combination with transplant.
Among the diseases that City of Hope physicians and scientists are targeting with CAR T cell therapy are lymphoma, leukemia and glioblastoma, with trials for additional solid tumors opening in 2018 and beyond. City of Hope’s CAR T trials for glioblastoma
— a type of aggressive brain tumor — were the first of their kind in the world to inject reengineered CAR T cells directly into the tumor site and cerebrospinal fluid. A case report was published in 2016 in the New England Journal of Medicine
You may also be interested in